Sergliflozin etabonate

Sergliflozin_etabonate_2.svg

Sergliflozin etabonate is a pharmaceutical compound that belongs to the class of drugs known as sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). These drugs are primarily used in the management of type 2 diabetes mellitus by promoting the excretion of glucose through the urine.

Mechanism of Action

Sergliflozin etabonate works by inhibiting the action of the sodium-glucose co-transporter 2 (SGLT2) proteins in the proximal tubules of the kidneys. SGLT2 is responsible for the reabsorption of glucose from the urine back into the bloodstream. By inhibiting this transporter, sergliflozin etabonate reduces the reabsorption of glucose, leading to increased glucose excretion and lower blood glucose levels.

Clinical Use

Sergliflozin etabonate is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It may be used alone or in combination with other antidiabetic medications such as metformin, sulfonylureas, or insulin.

Side Effects

Common side effects of sergliflozin etabonate include urinary tract infections, increased urination, and genital yeast infections. More serious but less common side effects include ketoacidosis, acute kidney injury, and hypotension.

Contraindications

Sergliflozin etabonate is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It is also not recommended for patients with a history of serious hypersensitivity reactions to the drug.

Pharmacokinetics

After oral administration, sergliflozin etabonate is rapidly absorbed and converted to its active form, sergliflozin. The drug is primarily metabolized in the liver and excreted in the urine.

Research and Development

Sergliflozin etabonate is currently under investigation for its potential benefits in other conditions such as heart failure and chronic kidney disease. Ongoing clinical trials are evaluating its efficacy and safety in these populations.

See Also

• Sodium-glucose co-transporter 2 inhibitors
• Type 2 diabetes mellitus
• Metformin
• Insulin
• Ketoacidosis